KRAS and intestinal cancer: Instead, we observed a weak trend towards prolonged survival in the KRAS-driven intestinal cancer model (median survival of 502 days (VKrasG12D/+;SnailKI/+) vs 354 days (VKrasG12D/+); p = 0.29; Fig. 2h, i).